As of 2025-07-12, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -11.97 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.96 USD, the upside of Rocket Pharmaceuticals Inc is -504.54%.
Based on its market price of 2.96 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 504.54%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.97 - -11.97 | -11.97 | -504.54% |
| P/E | (20.40) - (45.22) | (33.29) | -1224.6% |
| DDM - Stable | (24.64) - (552.09) | (288.36) | -9842.0% |
| DDM - Multi | (0.39) - (6.79) | (0.74) | -125.0% |
| Market Cap (mil) | 318.91 |
| Beta | 1.44 |
| Outstanding shares (mil) | 107.74 |
| Enterprise Value (mil) | 290.35 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.60% |
| Cost of Debt | 5.00% |
| WACC | 7.35% |